Compare Novavax Inc (NVAX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Ulta Beauty Inc — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Ulta Beauty Inc trades at $542.26 (market cap $23.17B). The key difference: Ulta Beauty Inc is far larger — about 14.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | ULTA | |
|---|---|---|
Market Cap | $1.62B | $23.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $706.82 |
52-Week Low | $6.22 | $450.75 |
Enterprise Value | $1.20B | $25.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
ULTA Beauty trades at $549.23, down 2.64% today, but maintains strong technical support near $539-$530. The company reported solid Q2 2026 earnings with EPS of $6.55 beating expectations of $6.22, while raising full-year guidance. Revenue growth continues at 8.9% year-over-year, though profit margins show slight compression from 12.17% in 2023 to 10.63% in 2025. Analyst consensus remains bullish with a $644 price target representing 17% upside potential.
ULTA presents a compelling growth story with consistent earnings beats and strong institutional support, but faces margin pressure and competitive retail headwinds. The stock's current valuation at 20.54 P/E appears reasonable given its 46.12% ROE and market leadership position. Key risks include consumer spending sensitivity and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
